Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai United Imaging Healthcare Co., Ltd. (688271.SS)
Shanghai, SH, CN
Shanghai United Imaging Healthcare Co., Ltd. engages in the provision, development, and production of advanced medical imaging solutions, radiotherapy equipment, life science instruments, and intelligent digital solutions worldwide. The company provides molecular imaging products; and magnetic resonance imaging solutions. It also offers computed tomography equipment; digital radiography equipment; mammography equipment; angiography equipment; mobile C-arm equipment; and radiotherapy systems comprising uRT-linac 506c, uRT-linac 306, and Intelligent RT Cloud Ecosystem. In addition, it provides uVision, a remote vision system that enables real-time positioning observation and automatic field of view identification; a low-dose, 3D mammography platform; and Remote Vision and Exposure Control technology application, a handheld X-ray from UIH that enables accurate positioning while reducing exposure radiation. Further, the company offers United Neuro, a medical imaging software used to analyze functional magnetic resonance imaging and diffusion tensor imaging data, and U-VIEWER, software that helps in viewing DICOM images. Additionally, it provides training, monitoring, maintenance, and troubleshooting services. Shanghai United Imaging Healthcare Co., Ltd. was founded in 2011 and is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.60% | +1.80% | -0.44% | -5.78% | -11.36% | -9.15% | -13.71% | -17.06% | -37.08% | -37.08% | -37.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Specialties: +8.3%+34.0% ★ Q1'26: +17.3% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+48.1% ★ Q1'26: +6.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+14.2% Q1'26: -63.6% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+14.4% ★ Q1'26: +16.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+101.0% ★ Q1'26: +10.9% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.1% Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.09× ★ Q1'26: 0.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 14 EPS Ana. |
Dec 2027 18 Rev. Ana. 16 EPS Ana. |
Dec 2028 14 Rev. Ana. 11 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
10.30B
est: 10.67B (-3.4%)
|
13.80B
est: 13.29B (+3.8%)
|
16.68B
16.01B – 17.49B
+25.5% YoY
|
20.08B
18.08B – 21.99B
+20.4% YoY
|
24.25B
24.24B – 24.27B
+20.8% YoY
|
| EBITDA |
1.77B
est: 2.21B (-20.1%)
|
2.54B
est: 2.76B (-7.7%)
|
3.46B
3.32B – 3.63B
+25.5% YoY
|
4.16B
3.75B – 4.56B
+20.4% YoY
|
5.03B
5.02B – 5.03B
+20.8% YoY
|
| EBIT |
1.35B
est: 1.84B (-26.5%)
|
1.99B
est: 2.29B (-13.4%)
|
2.88B
2.76B – 3.02B
+25.5% YoY
|
3.47B
3.12B – 3.80B
+20.4% YoY
|
4.19B
4.18B – 4.19B
+20.8% YoY
|
| Net Income |
1.26B
est: 1.41B (-10.8%)
|
1.87B
est: 1.90B (-1.5%)
|
2.39B
2.22B – 2.57B
+26.1% YoY
|
3.04B
2.58B – 3.87B
+27.0% YoY
|
3.87B
3.30B – 4.34B
+27.2% YoY
|
| SGA |
896.31M
est: 1.05B (-14.9%)
|
1.01B
est: 1.31B (-22.7%)
|
1.65B
1.58B – 1.73B
+25.5% YoY
|
1.98B
1.79B – 2.17B
+20.4% YoY
|
2.40B
2.39B – 2.40B
+20.8% YoY
|
| EPS |
1.54
est: 1.73 (-10.7%)
|
2.28
est: 2.27 (+0.3%)
|
2.90
2.71 – 3.13
+27.4% YoY
|
3.63
3.15 – 4.72
+25.2% YoY
|
4.56
4.03 – 5.30
+25.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-10 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-09 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-05 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-04 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-03 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-02 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-01 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 2.27% | 1.81M | 0.79% |
| 2 | KraneShares ICBCUBS SSE Star Market 50 Index UCITS ETF KSTR.L | 1.67% | 1.13M | 0.82% |
| 3 | KraneShares SSE STAR Market 50 Index ETF KSTR | 1.65% | 6.37M | 0.89% |
| 4 | Amundi MSCI China Tech UCITS ETF USD CC1U.L | 1.28% | 3.74M | 0.55% |
| 5 | Amundi MSCI China Tech UCITS ETF EUR CC1.PA | 1.28% | 3.73M | 0.55% |
| 6 | Rayliant-ChinaAMC Transformative China Tech ETF CNQQ | 0.41% | 93.4K | 0.75% |
| 7 | Xtrackers Harvest MSCI China Tech 100 UCITS ETF 1C XCTE.L | 0.37% | 184.6K | 0.44% |
| 8 | Invesco MSCI China Technology All Shares Stock Connect UCITS ETF MCHT.L | 0.31% | 490.7K | 0.49% |
| 9 | HSBC MSCI China A UCITS ETF HMCT.L | 0.30% | 398.3K | 0.30% |
| 10 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.28% | 63.4K | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bao Jun | President & Director | — | male |
| Cai Tao | Board Secretary, Chief Investment Officer & Director | — | male |
| Fengua Xia | Senior Vice President | — | male |
| Hong Miao | Senior Vice President | — | male |
| Hongdi Li | Senior VP, CTO & Core Technician | — | male |
| Shengtan Guo | GM, Co-CEO & Director | — | male |
| Shumei Wang | Vice President | — | female |
| Yeheng Yu | Senior Vice President | — | female |
| Yunlei Lv | Vice President | — | male |
| Zhang Qiang | Chairman & Co-CEO | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688271.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
